NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 Memorial Sloan Kettering Cancer Center;
  • 2 The University of Texas MD Anderson Cancer Center;
  • 3 Fred & Pamela Buffett Cancer Center;
  • 4 Moffitt Cancer Center;
  • 5 Huntsman Cancer Institute at the University of Utah;
  • 6 University of Michigan Rogel Cancer Center;
  • 7 Vanderbilt-Ingram Cancer Center;
  • 8 Dana-Farber/Brigham and Women’s Cancer Center;
  • 9 Mayo Clinic Cancer Center;
  • 10 UC San Diego Moores Cancer Center;
  • 11 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 12 Roswell Park Comprehensive Cancer Center;
  • 13 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • 14 Abramson Cancer Center at the University of Pennsylvania;
  • 15 Stanford Cancer Institute;
  • 16 University of Wisconsin Carbone Cancer Center;
  • 17 University of Colorado Cancer Center;
  • 18 City of Hope National Medical Center;
  • 19 Kidney Cancer Coalition;
  • 20 Yale Cancer Center/Smilow Cancer Hospital;
  • 21 Massachusetts General Hospital Cancer Center;
  • 22 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 23 O'Neal Comprehensive Cancer Center at UAB;
  • 24 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 25 Fox Chase Cancer Center;
  • 26 Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 27 Duke Cancer Institute;
  • 28 UCLA Jonsson Comprehensive Cancer Center;
  • 29 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 30 St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;
  • 31 Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and
  • 32 National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 2.

    Moch H, Gasser T, Amin MB, . Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Leibovich BC, Lohse CM, Crispen PL, . Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:13091315.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Lipworth L, Morgans AK, Edwards TL, . Renal cell cancer histological subtype distribution differs by race and sex. BJU Int 2016;117:260265.

  • 5.

    Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 2018;36:18911898.

  • 6.

    Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol 2016;43:566574.

  • 7.

    National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. Accessed June 28, 2019. Available at: http://seer.cancer.gov/statfacts/html/kidrp.html

  • 8.

    U.S. Food & Drug Administration. FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. Accessed July 20, 2020. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma

    • Export Citation
  • 9.

    Pembrolizumab. Prescribing information. Merck; 2014. Accessed July 20, 2020. Available at: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

  • 10.

    Rini BI, Plimack ER, Stus V, . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:11161127.

  • 11.

    Lenvatinib. Prescribing information. Eisai; 2020. Accessed July 20, 2020. Available at: http://www.lenvima.com/pdfs/prescribing-information.pdf

  • 12.

    U.S. Food & Drug Administration. FDA approves lenvatinib in combination with everolimus for advanced renal cell carcinoma. Accessed July 20, 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/lenvatinib-combination-everolimus

    • PubMed
    • Export Citation
  • 13.

    Motzer RJ, Hutson TE, Glen H, . Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:14731482.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    de Velasco G, McKay RR, Lin X, . Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer 2017;15:652660.e651.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Hutson TE, Michaelson MD, Kuzel TM, . A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 685.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Menko FH, Maher ER, Schmidt LS, . Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014;13:637644.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Rednam SP, Erez A, Druker H, . Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e6875.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017;1:897907.

  • 19.

    Eijkelenkamp K, Osinga TE, de Jong MM, . Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. Fam Cancer 2017;16:123130.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49:255265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Menko FH, van Steensel MA, Giraud S, . Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol 2009;10:11991206.

  • 22.

    Star P, Goodwin A, Kapoor R, . Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer 2018;92:4853.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Ornstein DK, Lubensky IA, Venzon D, . Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol 2000;163:431433.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Pavlovich CP, Grubb RL III, Hurley K, . Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005;173:14821486.

  • 25.

    Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am 2012;39:133148.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Gill AJ, Hes O, Papathomas T, . Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014;38:15881602.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Singer EA, Vourganti S, Lin KY, . Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol 2012;188:20842088.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Everolimus. Prescribing information. Novartis; 2020. Accessed July 20, 2020. Available at: https://www.novartis.us/sites/www.novartis.us/files/afinitor.pdf

  • 29.

    Bissler JJ, Kingswood JC, Radzikowska E, . Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817824.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Srinivasan R, Su D, Stamatakis L, . Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib [abstract]. Eur J Cancer 2014;50:Abstract 8.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Jonasch E, McCutcheon IE, Gombos DS, . Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 2018;19:13511359.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 687 687 687
PDF Downloads 239 239 239
EPUB Downloads 0 0 0